Both NTA and NTB t-tau differentiated CJD from Alzheimer’s disease with an AUC of 99%, performing similarly to the mid-region assays (AUCs 90–98%; DeLong P > 0.089 for all comparisons) but significantly better that both N-p-tau assays (AUCs 67–81%; DeLongNTA-Np217,P < 0.0001; DeLongNTA-Np181, P = 0.0006; DeLongNTB-Np217,P < 0.0001; DeLongNTB-Np181, P = 0.0003; Fig. 4B). The gene discussed is MAPT; the disease is Alzheimer disease.